Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–141 of 141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Single-ventricle Clear all

Conditions: Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)
Interventions: SGLT2 inhibitors; Drug
Lead sponsor: Leiden University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • Grand Rapids, Michigan • New York, New York

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions: BYDUREON, Placebo; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Congenital Heart Disease
Interventions: transfusion strategy, Low Hb transfusion group; Other
Lead sponsor: University of Rochester; Other
Eligibility: 4 Months to 7 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy Volunteer
Interventions: S-648414, Placebo, Midazolam, Dolutegravir; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tricuspid Atresia, Hypoplastic Left Heart Syndrome, Unbalanced AV Canal
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 6 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Fontan Physiology, Frailty, Single Ventricle Heart Disease
Interventions: WE BEAT Group Wellness Education program - phase 1, HEART Club Home Exercise program - phase 2; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 13 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypoplastic Left Heart Syndrome, Hypoplastic Right-sided Heart Complex
Interventions: Ambrisentan, Placebo; Drug · Other
Lead sponsor: Kevin Hill; Other
Eligibility: 24 Months to 120 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Single-ventricle, Heart Diseases
Interventions: Colchicine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 20 Months to 5 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ventricular Repolarization
Interventions: DIC075V; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Heart Disease, Congenital, Single Ventricle, Hypoplastic Left Heart Syndrome
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure
Interventions: Finerenone (BAY94-8862), Placebo, Inspra (eplerenone); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,066 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more

Conditions: Single-ventricle, Pulmonary Vascular Resistance Abnormality, Superior Cavo-Pulmonary Anastomosis, Endothelin, Metabolomics
Interventions: Research Blood Sampling; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month to 2 Years
Enrollment: 50 participants
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Single Ventricle Physiology
Interventions: Passive range of motion (ROM) exercise; Other
Lead sponsor: Carelon Research; Other
Eligibility: 1 Day to 30 Days
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Houston, Texas • Salt Lake City, Utah

Conditions: Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions: Vasopressin, Arginine, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Weeks to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Single-ventricle
Interventions: Hands-free oral-positive pressure device (oPEP); Device
Lead sponsor: Tarek Alsaied; Other
Eligibility: 8 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Diseases
Interventions: BMS-394136, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Salisbury, Maryland • Ann Arbor, Michigan • Columbus, Ohio

Conditions: Congenital Heart Disease, Single-ventricle
Interventions: Transthoracic Echocardiogram or Cardiac MRI, Ventripoint Echocardiogram; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia
Interventions: Iron (ferrous sulfate); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 2 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Single-ventricle, Congenital Heart Disease
Interventions: Not listed
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Congenital Heart Disease With Fontan Circulation
Interventions: macitentan 10 mg; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts • Spokane, Washington

Search by objective public record fields.

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Transfusion Strategies in Pediatric Cardiothoracic Surgery

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

Biomarker Study for Heart Failure in Children With Single Ventricle Physiology

WE BEAT - HEART Club Fontan Wellness Project: A Virtual Resilience Promotion and Frailty Prevention Program

Ambrisentan in Single Ventricle

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Colchicine in Postoperative Fontan Patients

A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

Single Ventricle Outcome

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis

Training in Exercise Activities and Motion for Growth

Early Use of Vasopressin in Post-Fontan Management

Simple Non-invasive Breathing Device to Improve Pulmonary Flow Pusatility in Single Ventricle Post Fontan

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

Ventripoint Single Ventricle Study

Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease

Redesigning the Care Journey of Patients With Single-ventricle Congenital Heart Disease

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.